Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy

ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy

Presented By
Dr Shun Lu, Shanghai Chest Hospital, China
Presented by
Shun Lu Shanghai Chest Hospital, China
Conference
ELCC 2022
Trial
Phase 2
Doi
https://doi.org/10.55788/6cc648bd
In a large, phase 2 trial, the novel ROS1 rearrangement-targeting tyrosine kinase inhibitor unecritinib showed promising efficacy and a manageable safety profile as first-line treatment in ROS1 rearrangement-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). ROS1 rearrangement is present in 1–2% of patients with NSCLC. Initial treatment with crizotinib or entrectinib is recommended [1]. Unecritinib is a novel, small molecule receptor tyrosine kinase inhibitor targeting ALK, ROS1, and MET. Preclinical studies demonstrated a good tumor inhibition activity and duration. In a phase 1 trial, unecritinib achieved an objective response rate (ORR) of 62.5% at a recommended phase 2 dose of 300 mg twice daily [2]. Dr Shun Lu (Shanghai Chest Hospital, China) presented the results of the ensuing phase 2 trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on